{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:38:27Z","timestamp":1789519107759,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ymthe.2025.08.052","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:09:46Z","timestamp":1756742986000},"page":"6298-6313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["AAV delivery of artificial miRNA targeting MAPT for the reduction of tau pathology in Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"33","author":[{"given":"Jessica M.","family":"Hogestyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Wischhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thangaaishwarya","family":"Mahendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Goulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3589-8749","authenticated-orcid":false,"given":"Christian","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2564-3048","authenticated-orcid":false,"given":"Bradford","family":"Elmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.08.052_bib1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/alz.12362","article-title":"Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060)","volume":"17","author":"Rajan","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ymthe.2025.08.052_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymthe.2025.08.052_bib3","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","article-title":"Synergy between amyloid-beta and tau in Alzheimer's disease","volume":"23","author":"Busche","year":"2020","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2025.08.052_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61691-2","article-title":"Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities","volume":"14","author":"Soderberg","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.08.052_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102012","article-title":"Efficacy and safety of anti-amyloid-beta monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis","volume":"90","author":"Jeremic","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ymthe.2025.08.052_bib6","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1007\/s00415-024-12361-w","article-title":"Amyloid antibody therapy for early-stage Alzheimer's disease: a critical review of three recent trials","volume":"271","author":"Guiloff","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymthe.2025.08.052_bib7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","article-title":"Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease","volume":"42","author":"Arriagada","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.08.052_bib8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymthe.2025.08.052_bib9","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/brain\/awx243","article-title":"Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease","volume":"140","author":"Bejanin","year":"2017","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.08.052_bib10","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jamaneurol.2016.2078","article-title":"Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between beta-Amyloid and Tauopathy","volume":"73","author":"Wang","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2025.08.052_bib11","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease","volume":"139","author":"Ossenkoppele","year":"2016","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.08.052_bib12","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2025.08.052_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.08.052_bib14","article-title":"Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier","volume":"2","author":"Shin","year":"2022","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.ymthe.2025.08.052_bib15","article-title":"Design of the First-in-Human Study of IONIS-MAPTRx, a Tau-lowering Antisense Oligonucleotide","volume":"90","author":"Mignon","year":"2018","journal-title":"Patients With Alzheimer Disease"},{"key":"10.1016\/j.ymthe.2025.08.052_bib16","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","article-title":"Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial","volume":"80","author":"Edwards","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2025.08.052_bib17","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.08.052_bib18","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1523\/JNEUROSCI.5392-05.2006","article-title":"Tau protects microtubules in the axon from severing by katanin","volume":"26","author":"Qiang","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymthe.2025.08.052_bib19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1126\/science.1194653","article-title":"Tau reduction prevents Abeta-induced defects in axonal transport","volume":"330","author":"Vossel","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.08.052_bib20","doi-asserted-by":"crossref","first-page":"12887","DOI":"10.1523\/JNEUROSCI.2107-13.2013","article-title":"Antisense reduction of tau in adult mice protects against seizures","volume":"33","author":"DeVos","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymthe.2025.08.052_bib21","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.neurobiolaging.2012.12.003","article-title":"Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice","volume":"34","author":"Morris","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ymthe.2025.08.052_bib22","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1016\/j.neurobiolaging.2014.05.001","article-title":"Seizure resistance without parkinsonism in aged mice after tau reduction","volume":"35","author":"Li","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ymthe.2025.08.052_bib23","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/WNR.0b013e32818b2a0b","article-title":"14-3-3 proteins and protein phosphatases are not reduced in tau-deficient mice","volume":"18","author":"Fujio","year":"2007","journal-title":"Neuroreport"},{"key":"10.1016\/j.ymthe.2025.08.052_bib24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/369488a0","article-title":"Altered microtubule organization in small-calibre axons of mice lacking tau protein","volume":"369","author":"Harada","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.08.052_bib25","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1242\/jcs.114.6.1179","article-title":"Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice","volume":"114","author":"Dawson","year":"2001","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ymthe.2025.08.052_bib26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0304-3940(99)00964-7","article-title":"Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice","volume":"279","author":"Ikegami","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymthe.2025.08.052_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe1611","article-title":"Persistent repression of tau in the brain using engineered zinc finger protein transcription factors","volume":"7","author":"Wegmann","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.08.052_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129240","article-title":"Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging","volume":"4","author":"Mazur","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.08.052_bib29","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10928-021-09761-0","article-title":"A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration","volume":"48","author":"Monine","year":"2021","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ymthe.2025.08.052_bib30","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000202549","article-title":"Long-Term Follow-Up of Onasemnogene Abeparvovec Gene Therapy in Patients with Spinal Muscular Atrophy Type 1 (P7-9.006)","volume":"100","author":"Mendell","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.08.052_bib31","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gt.2017.71","article-title":"AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease","volume":"24","author":"Miniarikova","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.08.052_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau6414","article-title":"Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques","volume":"10","author":"Borel","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.08.052_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.08.052_bib34","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.94.15_supplement.4531","article-title":"Translation of AMT-130 Preclinical Data to Inform the Design of the First FDA-approved Human AAV Gene Therapy Clinical Trial in Adults with Early Manifest Huntington\u2019s Disease (4531)","volume":"94","author":"Reilmann","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.08.052_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gks797","article-title":"siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse","volume":"41","author":"Boudreau","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.08.052_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkl143","article-title":"Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC\/miR-155","volume":"34","author":"Chung","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.08.052_bib37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2353\/ajpath.2006.060002","article-title":"Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits","volume":"169","author":"Schindowski","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2025.08.052_bib38","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nprot.2014.043","article-title":"Mapping the miRNA interactome by cross-linking ligation and sequencing of hybrids (CLASH)","volume":"9","author":"Helwak","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2025.08.052_bib39","series-title":"Scalable and Deep Profiling of mRNA Targets for Individual microRNAs with Chimeric eCLIP","author":"Manakov","year":"2022"},{"key":"10.1016\/j.ymthe.2025.08.052_bib40","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.molcel.2014.03.049","article-title":"Unambiguous identification of miRNA:target site interactions by different types of ligation reactions","volume":"54","author":"Grosswendt","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymthe.2025.08.052_bib41","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2025.08.052_bib42","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ymthe.2025.08.052_bib43","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.17126","article-title":"Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease","volume":"2","author":"Llibre-Guerra","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ymthe.2025.08.052_bib44","doi-asserted-by":"crossref","DOI":"10.1172\/JCI185001","article-title":"Cross-species efficacy of AAV-mediated ARSA replacement for metachromatic leukodystrophy","volume":"135","author":"Ramachandran","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.08.052_bib45","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer's disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat. Aging"},{"key":"10.1016\/j.ymthe.2025.08.052_bib46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer's disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.08.052_bib47","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41591-023-02505-2","article-title":"Emerging diagnostics and therapeutics for Alzheimer disease","volume":"29","author":"Self","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.08.052_bib48","doi-asserted-by":"crossref","first-page":"13300","DOI":"10.1523\/JNEUROSCI.0881-13.2013","article-title":"Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer's disease","volume":"33","author":"Polydoro","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymthe.2025.08.052_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.08.052_bib50","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.1113694","article-title":"Tau suppression in a neurodegenerative mouse model improves memory function","volume":"309","author":"Santacruz","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.08.052_bib51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/brain\/awx320","article-title":"Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia","volume":"141","author":"Lowe","year":"2018","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.08.052_bib52","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2967\/jnumed.120.257824","article-title":"Relationship Between Tau and Cognition in the Evolution of Alzheimer's Disease: New Insights from Tau PET","volume":"62","author":"Tanner","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ymthe.2025.08.052_bib53","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/mds.29322","article-title":"Why Therapeutic Trials Fail in Primary Tauopathies","volume":"38","author":"Olfati","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.08.052_bib54","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1093\/brain\/awy117","article-title":"Tau reduction in the presence of amyloid-beta prevents tau pathology and neuronal death in vivo","volume":"141","author":"DeVos","year":"2018","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.08.052_bib55","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.1141736","article-title":"Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model","volume":"316","author":"Roberson","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.08.052_bib56","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","article-title":"Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models","volume":"142","author":"Ittner","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.08.052_bib57","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.ajpath.2012.08.012","article-title":"Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP\/PS1 mice","volume":"181","author":"Leroy","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2025.08.052_bib58","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.ymthe.2021.07.010","article-title":"A comprehensive study of a 29-capsid AAV library in a non-human primate central nervous system","volume":"29","author":"Kondratov","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.052_bib59","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.ymthe.2024.05.040","article-title":"In vivo selection in non-human primates identifies AAV capsids for on-target CSF delivery to spinal cord","volume":"32","author":"Hanlon","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.052_bib60","article-title":"Scalable and deep profiling of mRNA targets for individual microRNAs with chimeric eCLIP","author":"Manakov","year":"2022","journal-title":"bioRxiv"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625007269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625007269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T13:52:57Z","timestamp":1766152377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625007269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1525001625007269"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.052","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV delivery of artificial miRNA targeting MAPT for the reduction of tau pathology in Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sanofi. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}